Clinical trial
A Phase 0/2 Study of Abemaciclib in Recurrent Glioblastoma
NCT02981940 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 0/2 Study of Abemaciclib in Recurrent Glioblastoma
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 9, 2017
- Completion date
- June 30, 2027
- Enrollment
- 45 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.